Abstract
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled GDC-0214, a JAK1 Inhibitor, as Single- and Multiple-Ascending Doses in Healthy Volunteers
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have